Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Xin Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie E. Lesnick, Esteban Braggio, Elisabeth M. Paietta, Susan O'Brien, Jacqueline C. Barrientos, Jose Francisco Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Harry Erba, Richard Stone, Mark R. Litzow, Martin S. TallmanTait D. Shanafelt, Neil E. Kay

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds